Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan Met Primary Endpoint
11/20/2026
Impact: 65
Healthcare
Merck said its Phase 3 TroFuse-015 trial of investigational sacituzumab tirumotecan met its primary endpoint of overall survival in patients with third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. The company said further trial data and clinical implications will be presented at upcoming medical forums. The announcement marks a development in Merck’s oncology pipeline; no financial results or stock-price impact were reported.
AI summary, not financial advice
Share: